Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt

Author

Yong-xian Hu

h-index 36 View on Semantic Scholar

We have 4 of 293 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Comparative clinical outcomes and single-cell profiling of CD19 CAR-T versus blinatumomab for relapsed/refractory B-ALL

Abstract Background CD19-targeting chimeric antigen receptor T-cells (CAR-T) and blinatumomab represent two leading immunotherapies for relapsed/refractory B cell acute lymphoblastic leukemia (r/r B-ALL). Despite sharing the same target, their differential clinical efficacy and underlying mechanisms remain unclear. Met...

Ke-Xin Wang, Lei Yu, Xing-Hua Liang et al. · 0 citations
Open access Jul 2026

Ultralow-Dose Interleukin 10-Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nonrandomized Clinical Trial.

The results of this nonrandomized clinical trial suggest that ultralow-dose META 10-19 demonstrated promising antitumor activity and a manageable safety profile in patients with R/R DLBCL.

Yong-Xian Hu, Ming-Ming Zhang, M. Gao et al. · 1 citation
Review Jul 2026

Optimizing CAR-T Therapy in Diffuse Large B-Cell Lymphoma: Biological Determinants and Translational Strategies Across the Therapeutic Continuum.

A clinically oriented synthesis of strategies to improve CAR-T efficacy in DLBCL, focusing on two interconnected objectives: enhancing initial remission and sustaining long-term disease control, is provided.

Yi-Shan Wang, Yong-Xian Hu · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.